Description
Amoxapine Tablets (25 mg / 50 mg / 100 mg / 150 mg)
Healthy Inc is a specialized global supplier and exporter of advanced CNS, psychiatry, and targeted neurological therapeutics. We provide ultra-high-purity, kinetically optimized Amoxapine Tablets, manufactured in WHO–GMP certified, high-precision specialized CNS facilities. This “Secondary Amine TCA” is a strategic export to mental health hospitals, neurology clinics, and government health ministries, serving as the globally mandated intervention for Endogenous Depression and Psychotic Depressive Disorders.
Product Overview
This formulation operates as a “Dual-Circuit Stabilizer.” Amoxapine is unique among antidepressants because it is chemically related to the antipsychotic drug Loxapine, allowing it to treat the mind and the mood simultaneously.
Mechanism 1 (Norepinephrine Reuptake Inhibition): Amoxapine strongly inhibits the reuptake of Norepinephrine (and to a lesser extent, Serotonin) at the synaptic cleft. This increases the availability of these “feel-good” chemicals, physically lifting the patient’s mood and energy levels.
Mechanism 2 (Dopamine $D_2$ Receptor Antagonism): Unlike almost all other antidepressants, Amoxapine blocks dopamine receptors. This provides an integrated Antipsychotic effect, making it exceptionally effective for depressed patients experiencing agitation, delusions, or paranoia.
Mechanism 3 (Rapid Clinical Onset): Clinical data suggests that Amoxapine often shows a therapeutic response within 4 to 7 days, which is significantly faster than many traditional SSRIs that require 2 to 4 weeks to take effect.
Product Composition & Strength
We supply this product in a full range of strengths to allow for precise clinical titration, packed in high-barrier Alu-Alu blister strips.
| Active Ingredient | Strength | Primary Clinical Function |
| Amoxapine USP/BP | 25 mg / 50 mg | The Titration Unit: Used for gradual dose escalation to minimize initial sedative effects. |
| Amoxapine USP/BP | 100 mg | The Standard Anchor: The primary maintenance dose for outpatients with moderate depression. |
| Amoxapine USP/BP | 150 mg | The High-Potency Payload: For hospitalized patients with severe psychotic or endogenous depression. |
Technical & Logistics Specifications
HS Code: 3004.90.79 (Other medicaments acting on the CNS – Antidepressants)
CAS Number: 14028-44-5 (Amoxapine)
Dosage Form: Uncoated or Film-Coated Tablet
Packaging: Alu-Alu Blisters. Protects the API from light and environmental humidity; our moisture-lock packaging ensures 24-month stability in Zone IVb tropical climates.
Manufacturing Authority & Compliance
API Purity Excellence: Our manufacturing process focuses on absolute chemical stability, ensuring the metabolite (7-hydroxyamoxapine) maintains its potent dopamine-blocking activity for consistent clinical results.
Neuro-Grade Containment: We utilize Segregated CNS Production Blocks to ensure zero cross-contamination, meeting the strictest international regulatory standards for psychiatric medication.
Primary Indications
Psychiatry: Treatment of Neurotic or Reactive Depressive Disorders and Endogenous Depression.
Specialist Care: Management of Depression accompanied by Anxiety or Agitation.
Critical Care: First-line choice for Psychotic Depression (Depression with delusions/hallucinations).
Dosage & Administration
Standard Adult Dosing: Initially 50 mg two or three times daily. Depending on tolerance, this may be increased to 300 mg daily.
Administration: Can be taken with or without food. Sedative effects may be managed by taking the largest portion of the dose at bedtime.
Safety Warning: Tardive Dyskinesia Risk. Due to its dopamine-blocking action, long-term use carries a risk of involuntary muscle movements. Monitor for Suicidal Ideation and anticholinergic effects (dry mouth, blurred vision). Strictly contraindicated during the acute recovery phase following a myocardial infarction (heart attack).
Global Export & Contract Manufacturing
Healthy Inc is a premier CNS Pharmaceutical Exporter in India. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) for specialized Tricyclic Antidepressants. Whether you are a Mental Health Hospital Network in Africa or a B2B Pharma Marketplace partner in the CIS, we ensure secure, WHO-GMP compliant delivery.









Reviews
There are no reviews yet.